Assay:99% Application:The next generation of oral selective estrogen receptor lowering agent (SERD) Giredestrant (formerly known as GDC 9545) neoadjuvant therapy for ER-positive, HER2-negative postmenopausal patients with
Min. Order:1Gram
Supplier:Senova Technology Company Limited [ China (Mainland)]
Premium
Supplier
Tel:+86-755-33372138
Address:Room2012, Tower A of Shangmei International Building, 1355# Liuxian Avenue, Nanshan Dist., Shenzhen, China 518055